NASDAQ$ABOS
Acumen Pharmaceuticals Inc · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
Acumen Pharmaceuticals reported first quarter 2025 financial results and business highlights, including the status of their Phase 2 ALTITUDE-AD study and cash position.
Acumen Pharmaceuticals reported a net loss of $28.8 million for the first quarter of 2025, an increase from the prior year, primarily driven by higher research and development expenses related to their Phase 2 clinical trial. The company ended the quarter with $197.9 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into early 2027.
- Net loss for Q1 2025 was $28.8 million, compared to $14.9 million in Q1 2024, primarily due to increased R&D expenses.
- Research and Development expenses significantly increased to $25.3 million in Q1 2025 from $12.4 million in the prior year.
- Cash, cash equivalents, and marketable securities totaled $197.9 million as of March 31, 2025.
- The company expects topline results from the Phase 2 ALTITUDE-AD study in late 2026.
Headline financials
Revenue & EPS history
Acumen · Revenue · Quarterly
$0
Forward guidance
Acumen Pharmaceuticals expects their current cash, cash equivalents, and marketable securities to fund operations into early 2027. They anticipate reporting topline results from the Phase 2 ALTITUDE-AD study in late 2026.
Tailwinds
- Cash position is expected to support operations into early 2027.
- Phase 2 ALTITUDE-AD study is fully enrolled.
- Topline results from ALTITUDE-AD expected in late 2026.
- ALTITUDE-AD is a sizable study with 542 participants.
- Sabirnetug has Fast Track designation from the FDA.
Headwinds
- Company is in a clinical stage and not yet generating revenue.
- Significant net loss for the quarter driven by R&D.
- Reliance on successful clinical trial outcomes for future viability.
- No specific financial guidance provided beyond cash runway.
- Results from the key Phase 2 trial are still over a year away.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2025
+0.6%
Avg return
Earnings day
-3.4%
Avg return
5 days after
-6.1%
Avg return
30 days after
42%
8 / 19 earnings
Positive
+35.9%
Q1 2023
Best reaction
-21.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.5% | -11.7% | — | |
| Q4 2025 | -2.3% | -10.3% | -2.3% | |
| Q3 2025 | -1.5% | -19.8% | +8.6% | |
| Q1 2025 | +0.0% | +1.9% | +8.6% | |
| Q4 2024 | +6.0% | -7.3% | -6.9% | |
| Q3 2024 | -21.4% | -25.5% | -35.7% | |
| Q2 2024 | -1.6% | +0.4% | -4.3% | |
| Q1 2024 | +13.1% | +8.6% | -21.4% | |
| Q4 2023 | -3.5% | +8.0% | -20.6% | |
| Q3 2023 | +12.1% | +20.0% | +53.2% | |
| Q2 2023 | -3.1% | +2.0% | -19.9% | |
| Q1 2023 | +35.9% | +15.5% | +0.4% | |
| Q4 2022 | +2.3% | +3.6% | -4.1% | |
| Q3 2022 | -5.1% | -10.6% | -15.3% | |
| Q2 2022 | +4.6% | -11.5% | +9.4% | |
| Q1 2022 | +9.6% | +4.5% | +7.8% | |
| Q4 2021 | -14.8% | -22.0% | -22.2% | |
| Q3 2021 | -17.1% | -23.9% | -46.7% | |
| Q2 2021 | +1.6% | +13.9% | +1.1% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro